FMP
Organovo Holdings, Inc.
ONVO
NASDAQ
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. The company was incorporated in 2007 and is headquartered in Solana Beach, California.
0.34 USD
-0.0061 (-1.79%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Mr. Keith E. Murphy
sector
Healthcare
industry
Biotechnology
website
https://www.organovo.comexchange
NASDAQ
Description
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. The company was incorporated in 2007 and is headquartered in Solana Beach, California.
CIK
0001497253
ISIN
US68620A2033
CUSIP
68620A203
Address
11555 Sorrento Valley Road
Phone
858 224 1000
Country
US
Employee
12
IPO Date
Feb 14, 2012
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
ONVO Financial Summary
CIK
0001497253
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
68620A203
ISIN
US68620A2033
Country
US
Price
0.34
Beta
0.61
Volume Avg.
153.38k
Market Cap
5.22M
Shares
-
52-Week
0.32-1.74
DCF
0.16
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.33
P/B
-
Website
https://www.organovo.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest ONVO News
It looks like there's no news available.
